<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[The Medicines Company 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=22424></link><description><![CDATA[The Medicines Company 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 04 Apr 2026 15:00:21 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2014/05/740813719_20140522162020_1173626900.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal]]></title><link>https://www.newswire.co.kr/newsRead.php?no=751391</link><description><![CDATA[PARIS--(Business Wire/Korea Newswire)--During the Late Breaking Clinical Trial sessions at EuroPCR yesterday and published simultaneously in the European Heart Journal, Professor Uwe Zeymer of Klinikum Ludwigshafen, Ludwigshafen, Germany and others reported a paper entitled: “Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment ele...]]></description><pubDate>Thu, 22 May 2014 20:00:00 +0900</pubDate></item><item><title><![CDATA[‘안지옥스’(비발리루딘 주)의 심근경색 환자 대상 임상 결과, 유로PCR학술회의 발표 및 유럽심장학회지 게재]]></title><link>https://www.newswire.co.kr/newsRead.php?no=751392</link><description><![CDATA[파리--(Business Wire/뉴스와이어)--독일 루트비히스하펜 병원(Klinikum Ludwigshafen)의 우베 자이머(Uwe Zeymer) 교수를 비롯한 연구원들은 어제 열린 유로PCR(중합효소연쇄반응) 연례 학술회의 ‘최신주요 임상시험’ 세션에서 “‘비발리루딘’(bivalirudin)이 1차 경피적 관상중재술을 받기 위해 긴급 이송된 ST분절 상승 심근경색(STEMI) 환자에 대해 헤파린제제 단독 사용 또는GP IIb/IIIa억제제를 긴급 병용...]]></description><pubDate>Thu, 22 May 2014 20:00:00 +0900</pubDate></item></channel></rss>